FERMT2

Across TCGA pan-cancer cohorts, FERMT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FERMT2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FERMT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FERMT2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where FERMT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.821	1.000	.005	15	view →
GBM	DFS	Quartile	All	0.253	0.454	.011	8	view →
LSCC	DFS	Quartile	II,III,IV	0.529	0.877	.022	7	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	7	view →
CCRCC	DFS	Quartile	III,IV	0.814	0.318	<.001	5	view →
HNSC	DFS	Quartile	All	0.532	0.756	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FERMT2–LUAD (DFS)

Open the LUAD breakdown →